Tags

Type your tag names separated by a space and hit enter

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
PLoS One. 2017; 12(8):e0183191.Plos

Abstract

BACKGROUND

The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results of immunogenicity studies and correlates of protection derived from randomized clinical trials of the 7-valent conjugate pneumococcal vaccine. We assessed the vaccination effectiveness (VE) of the PCV13 in preventing invasive pneumococcal disease (IPD) in children aged 7-59 months in a population with suboptimal vaccination coverage of 55%.

METHODS

The study was carried out in children with IPD admitted to three hospitals in Barcelona (Spain) and controls matched by hospital, age, sex, date of hospitalization and underlying disease. Information on the vaccination status was obtained from written medical records. Conditional logistic regression was made to estimate the adjusted VE and 95% confidence intervals (CI).

RESULTS

169 cases and 645 controls were included. The overall VE of ≥1 doses of PCV13 in preventing IPD due to vaccine serotypes was 75.8% (95% CI, 54.1-87.2) and 90% (95% CI, 63.9-97.2) when ≥2 doses before 12 months, two doses on or after 12 months or one dose on or after 24 months, were administered. The VE of ≥1 doses was 89% (95% CI, 42.7-97.9) against serotype 1 and 86.0% (95% CI, 51.2-99.7) against serotype 19A. Serotype 3 showed a non-statistically significant effectiveness (25.9%; 95% CI, -65.3 to 66.8).

CONCLUSIONS

The effectiveness of ≥1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes in children aged 7-59 months was good and, except for serotype 3, the effectiveness of ≥1 doses against the most frequent PCV13 serotypes causing IPD was high when considered individually.

Authors+Show Affiliations

Departament de Medicina, Universitat de Barcelona, Barcelona, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain.Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain.CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Malalties Prevenibles amb vacunes, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. Hospital Sant Joan de Déu Barcelona, Universitat de Barcelona, Barcelona, Spain.Departament de Medicina, Universitat de Barcelona, Barcelona, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Barcelona, Spain.Hospital Universitari Vall d'Hebron, Barcelona, Spain.Hospital de Nens, Barcelona, Spain.CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Malalties Prevenibles amb vacunes, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. Hospital Sant Joan de Déu Barcelona, Universitat de Barcelona, Barcelona, Spain.Hospital Universitari Vall d'Hebron, Barcelona, Spain.Hospital Universitari Vall d'Hebron, Barcelona, Spain. Grup de Recerca en Epidemiologia i Salut Pública, Vall d'Hebron Institut de Recerca, Barcelona, Spain.Hospital Universitari Vall d'Hebron, Barcelona, Spain. Grup de Recerca en Epidemiologia i Salut Pública, Vall d'Hebron Institut de Recerca, Barcelona, Spain.Hospital Sant Joan de Déu Barcelona, Universitat de Barcelona, Barcelona, Spain.Hospital Sant Joan de Déu Barcelona, Universitat de Barcelona, Barcelona, Spain.Hospital Universitari Vall d'Hebron, Barcelona, Spain.CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Malalties Prevenibles amb vacunes, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. Hospital Sant Joan de Déu Barcelona, Universitat de Barcelona, Barcelona, Spain.Hospital Universitari Vall d'Hebron, Barcelona, Spain.CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Malalties Prevenibles amb vacunes, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. Hospital Sant Joan de Déu Barcelona, Universitat de Barcelona, Barcelona, Spain. Departament de Medicina, Universitat Internacional de Catalunya, Barcelona, Spain.Departament de Medicina, Universitat de Barcelona, Barcelona, Spain. CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28806737

Citation

Domínguez, Ángela, et al. "Effectiveness of the 13-valent Pneumococcal Conjugate Vaccine in Preventing Invasive Pneumococcal Disease in Children Aged 7-59 Months. a Matched Case-control Study." PloS One, vol. 12, no. 8, 2017, pp. e0183191.
Domínguez Á, Ciruela P, Hernández S, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PLoS One. 2017;12(8):e0183191.
Domínguez, Á., Ciruela, P., Hernández, S., García-García, J. J., Soldevila, N., Izquierdo, C., Moraga-Llop, F., Díaz, A., F de Sevilla, M., González-Peris, S., Campins, M., Uriona, S., Martínez-Osorio, J., Solé-Ribalta, A., Codina, G., Esteva, C., Planes, A. M., Muñoz-Almagro, C., & Salleras, L. (2017). Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PloS One, 12(8), e0183191. https://doi.org/10.1371/journal.pone.0183191
Domínguez Á, et al. Effectiveness of the 13-valent Pneumococcal Conjugate Vaccine in Preventing Invasive Pneumococcal Disease in Children Aged 7-59 Months. a Matched Case-control Study. PLoS One. 2017;12(8):e0183191. PubMed PMID: 28806737.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. AU - Domínguez,Ángela, AU - Ciruela,Pilar, AU - Hernández,Sergi, AU - García-García,Juan José, AU - Soldevila,Núria, AU - Izquierdo,Conchita, AU - Moraga-Llop,Fernando, AU - Díaz,Alvaro, AU - F de Sevilla,Mariona, AU - González-Peris,Sebastià, AU - Campins,Magda, AU - Uriona,Sonia, AU - Martínez-Osorio,Johanna, AU - Solé-Ribalta,Anna, AU - Codina,Gemma, AU - Esteva,Cristina, AU - Planes,Ana María, AU - Muñoz-Almagro,Carmen, AU - Salleras,Luis, Y1 - 2017/08/14/ PY - 2017/05/02/received PY - 2017/07/31/accepted PY - 2017/8/15/entrez PY - 2017/8/15/pubmed PY - 2017/10/11/medline SP - e0183191 EP - e0183191 JF - PloS one JO - PLoS One VL - 12 IS - 8 N2 - BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results of immunogenicity studies and correlates of protection derived from randomized clinical trials of the 7-valent conjugate pneumococcal vaccine. We assessed the vaccination effectiveness (VE) of the PCV13 in preventing invasive pneumococcal disease (IPD) in children aged 7-59 months in a population with suboptimal vaccination coverage of 55%. METHODS: The study was carried out in children with IPD admitted to three hospitals in Barcelona (Spain) and controls matched by hospital, age, sex, date of hospitalization and underlying disease. Information on the vaccination status was obtained from written medical records. Conditional logistic regression was made to estimate the adjusted VE and 95% confidence intervals (CI). RESULTS: 169 cases and 645 controls were included. The overall VE of ≥1 doses of PCV13 in preventing IPD due to vaccine serotypes was 75.8% (95% CI, 54.1-87.2) and 90% (95% CI, 63.9-97.2) when ≥2 doses before 12 months, two doses on or after 12 months or one dose on or after 24 months, were administered. The VE of ≥1 doses was 89% (95% CI, 42.7-97.9) against serotype 1 and 86.0% (95% CI, 51.2-99.7) against serotype 19A. Serotype 3 showed a non-statistically significant effectiveness (25.9%; 95% CI, -65.3 to 66.8). CONCLUSIONS: The effectiveness of ≥1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes in children aged 7-59 months was good and, except for serotype 3, the effectiveness of ≥1 doses against the most frequent PCV13 serotypes causing IPD was high when considered individually. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/28806737/Effectiveness_of_the_13_valent_pneumococcal_conjugate_vaccine_in_preventing_invasive_pneumococcal_disease_in_children_aged_7_59_months__A_matched_case_control_study_ L2 - https://dx.plos.org/10.1371/journal.pone.0183191 DB - PRIME DP - Unbound Medicine ER -